Anisur Rahman

List of Publications by Year in Descending Order

154 papers	9,003 citations	40 h-index	93 g-index
196 ext. papers	10,853 ext. citations	5.2 avg, IF	5.77 L-index

#	Paper	IF	Citations
154	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome.. *Frontiers in Immunology*, **2022**, 13, 842923	8.4	
153	Flares in patients with systemic lupus erythematosus. *Rheumatology*, **2021**, 60, 3262-3267	3.9	2
152	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. *Arthritis Care and Research*, **2021**, 73, 1231-1235	4.7	10
151	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. *Annals of the Rheumatic Diseases*, **2021** ,	2.4	4
150	2021 DORIS definition of remission in SLE: final recommendations from an international task force. *Lupus Science and Medicine*, **2021**, 8,	4.6	7
149	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. *Arthritis Care and Research*, **2021**, 73, 1789-1795	4.7	2
148	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 1446-1458	9.4	6
147	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. *Lupus*, **2021**, 30, 1283-1288	2.6	2
146	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. *Arthritis and Rheumatology*, **2021**, 73, 2293-2302	9.5	2
145	Antiphospholipid syndrome and pregnancy. *British Journal of Midwifery*, **2021**, 29, 308-309	0.3	
144	Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus. *Expert Review of Clinical Immunology*, **2021**, 17, 957-967	5.1	6
143	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. *Rheumatology*, **2021**, 60, 4185-4198	3.9	0
142	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. *Scientific Reports*, **2021**, 11, 4542	4.9	2
141	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. *Rheumatology*, **2021**, 60, 4737-4747	3.9	5
140	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. *Lupus Science and Medicine*, **2021**, 8,	4.6	5
139	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). *Arthritis Care and Research*, **2020**,	4.7	2
138	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. *Arthritis and Rheumatology*, **2020**, 72, 1734-1740	9.5	7

137	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. *Scientific Reports*, **2020**, 10, 3102	4.9	2
136	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. *Rheumatology*, **2020**, 59, 524-533	3.9	10
135	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. *Arthritis Care and Research*, **2020**, 72, 1800-1808	4.7	7
134	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. *Arthritis and Rheumatology*, **2020**, 72, 658-666	9.5	11
133	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. *Journal of Autoimmunity*, **2020**, 106, 102340	15.5	15
132	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. *Annals of the Rheumatic Diseases*, **2020**, 79, 356-362	2.4	18
131	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. *Lupus*, **2020**, 29, 1571-1593	2.6	27
130	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2020**, 47, 72-81	4.1	21
129	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis and Rheumatology*, **2020**, 72, 67-77	9.5	18
128	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. *Blood Reviews*, **2020**, 39, 100610	11.1	42
127	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. *Rheumatology*, **2020**, 59, 146-152	3.9	6
126	Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. *Rheumatology*, **2020**, 59, 3314-3323	3.9	3
125	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. *Journal of Rheumatology*, **2019**, 46, 492-500	4.1	7
124	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. *BMJ Open*, **2019**, 9, e028697	2	13
123	Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. *Lupus*, **2019**, 28, 916-917	2.6	2
122	Domain I of β2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation. *Lupus*, **2019**, 28, 893-897	2.6	1
121	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2019**, 71, 1297-1307	9.5	15
120	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. *Rheumatology*, **2019**, 58, 1259-1267	3.9	5

119	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. *Arthritis Care and Research*, **2019**, 71, 893-902	4.7	46
118	Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol. *BMJ Open*, **2019**, 9, e028937	3	5
117	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. *Annals of the Rheumatic Diseases*, **2019**, 78, 1010-1012	2.4	4
116	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes **2019**, 355-365		0
115	Antilipoprotein and Antiendothelial Cell Antibodies **2019**, 375-376		
114	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis and Rheumatology*, **2019**, 71, 281-289	9.5	31
113	Red cell distribution width correlates with fatigue levels in a diverse group of patients with systemic lupus erythematosus irrespective of anaemia status. *Clinical and Experimental Rheumatology*, **2019**, 37, 852-854	2.2	3
112	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. *Journal of Rheumatology*, **2018**, 45, 393-396	4.1	23
111	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. *Rheumatology*, **2018**, 57, 677-687	3.9	20
110	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis Care and Research*, **2018**, 70, 1478-1487	4.7	36
109	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. *Rheumatology*, **2018**, 57, 470-479	3.9	47
108	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. *Arthritis Care and Research*, **2018**, 70, 98-103	4.7	18
107	Managing conventional cardiovascular risk factors in the lupus clinic - what can we achieve?. *Lupus*, **2018**, 27, 172-173	2.6	
106	Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. *Clinical Reviews in Allergy and Immunology*, **2018**, 55, 352-367	12.3	51
105	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. *Journal of Autoimmunity*, **2018**, 93, 114-123	15.5	13
104	140 Evaluating the prevalence of iron deficiency and anaemia in systemic lupus erythematosus. *Rheumatology*, **2018**, 57,	3.9	1
103	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. *Arthritis Care and Research*, **2018**, 70, 1294-1302	4.7	13
102	Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. *BMJ Open*, **2018**, 8, e019491	3	28

101	132 Going viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. *Rheumatology*, **2018**, 57,	3.9	1
100	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. *Frontiers in Immunology*, **2018**, 9, 2413	8.4	8
99	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. *Rheumatology Advances in Practice*, **2018**, 2, rky003	1.1	8
98	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. *Frontiers in Immunology* , **2018**, 9, 2244	8.4	8
97	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). *Annals of the Rheumatic Diseases*, **2017**, 76, 554-561	2.4	175
96	A critical analysis of the tools to evaluate neuropsychiatric lupus. *Lupus*, **2017**, 26, 504-509	2.6	14
95	Atherosclerosis in systemic lupus erythematosus. *Best Practice and Research in Clinical Rheumatology*, **2017**, 31, 364-372	5.3	34
94	Oxidation of 2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. *PLoS ONE*, **2017**, 12, e0186513	3.7	8
93	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. *Cell Death and Disease*, **2017**, 8, e2549	9.8	13
92	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. *Scientific Reports*, **2017**, 7, 10788	4.9	5
91	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. *Rheumatology*, **2017**, 56, 1041-1043	3.9	1
90	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. *Arthritis Research and Therapy*, **2017**, 19, 287	5.7	1
89	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report **2017**, 317-338		16
88	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis **2017**, 77-116		3
87	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests **2017**, 171-187		2
86	The frequency and outcome of lupus nephritis: results from an international inception cohort study. *Rheumatology*, **2016**, 55, 252-62	3.9	210
85	The association between IgG and IgM antibodies against cardiolipin, 2-glycoprotein I and Domain I of 2-glycoprotein I with disease profile in patients with multiple sclerosis. *Molecular Immunology*, **2016**, 75, 161-7	4.3	12
84	Novel Three-Day, Community-Based, Nonpharmacological Group Intervention for Chronic Musculoskeletal Pain (COPERS): A Randomised Clinical Trial. *PLoS Medicine*, **2016**, 13, e1002040	11.6	34

83	Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England. *PLoS ONE*, **2016**, 11, e0151245	3.7	37
82	Improving the self-management of chronic pain: COping with persistent Pain, Effectiveness Research in Self-management (COPERS). *Programme Grants for Applied Research*, **2016**, 4, 1-440	1.5	11
81	Measuring IgA Anti-β2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. *PLoS ONE*, **2016**, 11, e0156407	3.7	50
80	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. *Arthritis and Rheumatology*, **2016**, 68, 1932-44	9.5	27
79	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. *Science Immunology*, **2016**, 1,	28	28
78	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. *Rheumatology*, **2016**, 55, 1243-50	3.9	19
77	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. *Arthritis Care and Research*, **2016**, 68, 1505-13	4.7	38
76	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. *Arthritis Research and Therapy*, **2015**, 17, 26	5.7	20
75	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. *Arthritis Research and Therapy*, **2015**, 17, 47	5.7	11
74	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. *Arthritis and Rheumatology*, **2015**, 67, 1837-47	9.5	77
73	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. *Rheumatology*, **2015**, 54, 722-7	3.9	49
72	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. *Annals of the Rheumatic Diseases*, **2015**, 74, 1530-6	2.4	51
71	Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. *Autoimmunity Reviews*, **2015**, 14, 153-9	13.6	87
70	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Annals of the Rheumatic Diseases*, **2015**, 74, 1706-13	2.4	250
69	New therapeutic avenues in SLE. *Best Practice and Research in Clinical Rheumatology*, **2015**, 29, 794-809	5.3	8
68	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. *BMC Biotechnology*, **2015**, 15, 104	3.5	6
67	Antibodies to domain I of β2-glycoprotein I and IgA antiphospholipid antibodies in patients with seronegative antiphospholipid syndrome. *Annals of the Rheumatic Diseases*, **2015**, 74, 317-9	2.4	35
66	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. *Arthritis Research and Therapy*, **2014**, 16, R48	5.7	4

65	Efficacy of an out-patient pain management programme for people with joint hypermobility syndrome. *Clinical Rheumatology*, **2014**, 33, 1665-9	3.9	13
64	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. *Annals of the Rheumatic Diseases*, **2014**, 73, 138-42	2.4	83
63	Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE. *Nature Reviews Rheumatology*, **2014**, 10, 71-2	8.1	9
62	Fibromyalgia. *BMJ, The*, **2014**, 348, g1224	5.9	64
61	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. *Arthritis Care and Research*, **2014**, 66, 1167-76	4.7	43
60	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. *Autoimmunity Reviews*, **2014**, 13, 917-30	13.6	186
59	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. *Lupus Science and Medicine*, **2014**, 1, e000013	4.6	5
58	PEGylated drugs in rheumatology--why develop them and do they work?. *Rheumatology*, **2014**, 53, 391-6	3.9	27
57	Cancer risk in systemic lupus: an updated international multi-centre cohort study. *Journal of Autoimmunity*, **2013**, 42, 130-5	15.5	194
56	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. *Arthritis and Rheumatism*, **2013**, 65, 2887-97		65
55	The research that time forgot. *British Journal of Hospital Medicine (London, England: 2005)*, **2013**, 74, 702-3	0.8	
54	Effectiveness and cost-effectiveness of a novel, group self-management course for adults with chronic musculoskeletal pain: study protocol for a multicentre, randomised controlled trial (COPERS). *BMJ Open*, **2013**, 3,	3	12
53	Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course. *BMJ Open*, **2013**, 3, e003534	3	18
52	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. *Annals of the Rheumatic Diseases*, **2013**, 72, 1308-14	2.4	65
51	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis and Rheumatism*, **2012**, 64, 2677-86		2688
50	Imaging assessment of cardiovascular disease in systemic lupus erythematosus. *Clinical and Developmental Immunology*, **2012**, 2012, 694143		16
49	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. *Annals of the Rheumatic Diseases*, **2012**, 71, 1502-9	2.4	115
48	Effective delivery styles and content for self-management interventions for chronic musculoskeletal pain: a systematic literature review. *Clinical Journal of Pain*, **2012**, 28, 344-54	3.5	99

47	Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of sub-group analysis within RCTs. *European Journal of Pain*, **2011**, 15, 775.e1-11	3.7	59
46	Evaluating the conformation of recombinant domain I of β(2)-glycoprotein I and its interaction with human monoclonal antibodies. *Molecular Immunology*, **2011**, 49, 56-63	4.3	14
45	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. *Arthritis and Rheumatism*, **2011**, 63, 2774-82		84
44	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. *Arthritis and Rheumatism*, **2011**, 63, 3512-21		11
43	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. *Rheumatology*, **2011**, 50, 982-8	3.9	120
42	Numerical scoring for the BILAG-2004 index. *Rheumatology*, **2010**, 49, 1665-9	3.9	84
41	Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. *Journal of Immunology*, **2010**, 184, 6622-8	5.3	58
40	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. *Journal of Rheumatology*, **2010**, 37, 322-9	4.1	65
39	Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. *Arthritis and Rheumatism*, **2010**, 62, 845-54		88
38	Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. *Journal of Immunology*, **2009**, 182, 4836-43	5.3	18
37	Numerical scoring for the Classic BILAG index. *Rheumatology*, **2009**, 48, 1548-52	3.9	31
36	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. *Rheumatology*, **2009**, 48, 673-5	3.9	160
35	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. *Rheumatology*, **2009**, 48, 691-5	3.9	74
34	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. *Arthritis Research and Therapy*, **2009**, 11, R154	5.7	88
33	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. *Rheumatology*, **2009**, 48, 573-5	3.9	21
32	Systemic lupus erythematosus. *New England Journal of Medicine*, **2008**, 358, 929-39	59.2	1367
31	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. *Current Rheumatology Reviews*, **2008**, 4, 2-11	1.6	2
30	Origin and structure of autoantibodies and antigens in autoimmune rheumatic diseases. *Lupus*, **2008**, 17, 232-5	2.6	5

29	Do high-sensitivity C-reactive protein levels help predict risk of cardiovascular disease in patients with osteoarthritis?. *Nature Clinical Practice Rheumatology*, **2008**, 4, 122-3		
28	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. *Arthritis and Rheumatism*, **2007**, 56, 280-90		115
27	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. *Arthritis and Rheumatism*, **2007**, 56, 2392-401		11
26	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. *Arthritis and Rheumatism*, **2007**, 56, 4113-9		76
25	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. *Arthritis and Rheumatism*, **2006**, 55, 892-9		81
24	Structure and function of autoantibodies and their role in autoimmune rheumatic diseases. *Expert Review of Clinical Immunology*, **2006**, 2, 225-36	5.1	1
23	Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. *Journal of Immunology*, **2006**, 177, 1729-36	5.3	27
22	Systemic lupus erythematosus. *Orphanet Journal of Rare Diseases*, **2006**, 1, 6	4.2	120
21	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies **2006**, 470-491		2
20	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. *BMC Biotechnology*, **2006**, 6, 8	3.5	30
19	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. *Arthritis Research and Therapy*, **2005**, 7, R971-83	5.7	13
18	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. *Arthritis Research*, **2005**, 7, R47-56		17
17	"It struck me that they didnR understand pain": the specialist pain clinic experience of patients with chronic musculoskeletal pain. *Arthritis and Rheumatism*, **2005**, 53, 691-6		48
16	Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. *Arthritis and Rheumatism*, **2004**, 50, 866-70		78
15	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. *Molecular Immunology*, **2004**, 40, 745-58	4.3	15
14	Important determinants of self-efficacy in patients with chronic musculoskeletal pain. *Journal of Rheumatology*, **2004**, 31, 1187-92	4.1	15
13	A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. *Seminars in Arthritis and Rheumatism*, **2003**, 32, 246-65	5.3	30
12	How do antiphospholipid antibodies bind beta2-glycoprotein I?. *Arthritis and Rheumatism*, **2003**, 48, 2111-21		50

11	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. *Molecular Immunology*, **2003**, 40, 49-60	4.3	25
10	Molecular expression systems for anti-DNA antibodies--1. *Lupus*, **2002**, 11, 824-32	2.6	7
9	Systematic analysis of sequences of anti-DNA antibodies--relevance to theories of origin and pathogenicity. *Lupus*, **2002**, 11, 807-23	2.6	36
8	Anti-DNA antibodies--structure and function. *Lupus*, **2002**, 11, 776-9	2.6	6
7	Anti-DNA antibodies--overview of assays and clinical correlations. *Lupus*, **2002**, 11, 770-3	2.6	29
6	Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. *Molecular Immunology*, **2002**, 39, 299-311	4.3	23
5	The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. *Journal of Molecular Biology*, **2001**, 307, 149-60	6.5	29
4	Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab. *Journal of Biological Chemistry*, **2000**, 275, 35129-36	5.4	17
3	Structure-function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. *Expert Reviews in Molecular Medicine*, **1999**, 1999, 1-28	6.7	3
2	Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. *Seminars in Arthritis and Rheumatism*, **1998**, 28, 141-54	5.3	26
1	The role of in vitro expression systems in the investigation of antibodies to DNA. *Seminars in Arthritis and Rheumatism*, **1998**, 28, 130-9	5.3	3